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SUMMARY
Background
Several prognostic models have emerged in alcoholic hepatitis (AH), but
lack of external validation precludes their universal use.
Aim
To validate the Maddrey Discriminant Function (DF); Glasgow Alcoholic
Hepatitis Score (GAHS); Mayo End-stage Liver Disease (MELD); Age, Biliru-
bin, INR, Creatinine (ABIC); MELD-Na, UK End-stage Liver Disease
(UKELD), and three scores of corticosteroid response at 1 week: an Early
Change in Bilirubin Levels (ECBL), a 25% fall in bilirubin, and the Lille score.
Methods
Seventy-one consecutive patients with biopsy-proven AH, admitted between
November 2007-September 2011, were evaluated. The clinical and biochem-
ical parameters were analysed to assess prognostic models with respect to
30- and 90-day mortality.
Results
There were no signiﬁcant differences in the areas under the receiver operat-
ing characteristics curve (AUROCs) relative to 30-day/90-day mortality:
MELD 0.79/0.84, DF 0.71/0.74, GAHS 0.75/0.78, ABIC 0.71/0.78, MELD-Na
0.68/0.76, UKELD 0.56/0.68. One-week rescoring yielded a trend towards
improved predictive accuracies (30-day/90-day AUROCs: 0.69–0.84/0.77–
0.86). In patients with admission DF ≥32 (n = 31), response to corticoster-
oids according to ECBL, 25% fall in bilirubin and the Lille model yielded
AUROCs of 0.73/0.73, 0.78/0.72 and 0.81/0.82 for a 30-day/90-day outcome
respectively. All models showed excellent negative predictive values (NPVs;
range: 86–100%), while the positive ones were low (range: 17–50%).
Conclusions
MELD, DF, GAHS, ABIC and scores of corticosteroid response proved to
be valid in an independent cohort of biopsy-proven alcoholic hepatitis.
MELD modiﬁcations incorporating sodium did not confer any prognostic
advantage over classical MELD. Based on excellent NPVs, the models are
best to identify patients at low risk of death.
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INTRODUCTION
Alcoholic hepatitis (AH) is an acute inﬂammatory hepa-
tic syndrome occurring in patients with alcohol misuse.1
However, the clinical phenotype of AH is very variable.
There are mild forms, likely to improve with conserva-
tive management, while severe cases have a high risk of
death even if treated.2 Currently, corticosteroids, pentox-
ifylline and N-acetylcysteine are the therapeutic
options,3–6 although treatment of AH remains controver-
sial.7 A survival beneﬁt conferred by steroids is indeed
disputed in standard meta-analysis,8, 9 but supported in
individual patient data analysis.10 An ongoing, ade-
quately powered, UK randomised controlled trial will
probably answer such therapeutic controversies.11 Due to
the potential adverse events associated with corticoster-
oids (mainly occurrence of sepsis), AH is currently
managed on a risk-beneﬁt basis. Thus, prognostic strati-
ﬁcation according to short-term mortality is paramount
both for disease management and to enable clinical trials
targeting new treatments in AH.
For over 3 decades, the Maddrey discriminant func-
tion (DF)12 has been the standard surrogate for the
assessment of disease severity and to guide treatment in
AH. A cut-off value of ≥32 identiﬁed patients who had
greater than 50% mortality at 30 days and therefore this
was instituted as the threshold for corticosteroid therapy.
Over the years, alternative prognostic scores have been
developed: the Glasgow alcoholic hepatitis score
(GAHS)13 and the age, bilirubin, international norma-
lised ratio, creatinine score (ABIC).14 Alongside these
disease-speciﬁc formulas, previous studies (including
34,15 7316 and 20217 patients) have outlined the utility of
the model for end-stage liver disease (MELD) for pre-
dicting mortality in AH, whereas the utility of the MELD
including sodium (MELD-Na) has been also assessed in
a small study.18 A further reﬁnement has been to assess
the response to corticosteroid treatment. In this context,
the Lille score19 with a threshold of 0.45 has been devel-
oped to identify patients with severe AH who might ben-
eﬁt from corticosteroids, whereas also use of GAHS with
a threshold of 9 has been proposed.20 Previously, any fall
in serum bilirubin levels after 1 week of corticosteroid
therapy (Early Change in Bilirubin Levels: ECBL),21 or
more speciﬁcally a 25% fall,22 have been proposed as
simple indicators of corticosteroid response.
In recent years, several prognostic models have
become available in AH, all of them advocated as best
by their respective authors. External validation and
model comparisons are therefore required to guide
selection among the models for use in routine clinical
practice. However, diagnosis of AH is challenging and
patients with other forms of hepatic decompensation
(such as decompensated cirrhosis with severe jaundice
and acute alcoholic steatosis) may be erroneously classi-
ﬁed as AH. This is more likely to happen when liver
biopsy is not performed, including a transjugular
approach which can obviate clotting problems.23 Indeed,
diagnosis of AH based on clinical grounds has been
associated with a 10–50% risk of misclassiﬁcation.24–26
Thus, in the present study, we aimed to cross-validate
nine prognostic indices for short-term mortality using an
independent cohort of patients with AH conﬁrmed by
transjugular liver biopsy. This is standard practice in our
centre whenever AH is suspected.
PATIENTS AND METHODS
Study population
Consecutive patients with a histological diagnosis of AH
by liver biopsy, between November 2007 and September
2011, were identiﬁed through a computerised pathology
register. All patients were referred for transjugular liver
biopsy by their treating physician (who was a hepatolo-
gist in all cases) due to the clinical suspicion of AH. The
patients’ clinical and biochemical features on admission
were compatible with a diagnosis of AH, according to
the following criteria: a) history of alcohol abuse within
the last 2 months (>40 g/day compatible with or men;
>20 g/day for women), b) total serum bilirubin exceeding
29 upper limit of normality (ULN = 17 lmol/L), c)
aspartate to alanine aminotransferase ratio exceeding 1.5
with aspartate aminotransferase over 45 U/L and c)
absence of concomitant primary cause of liver disease.
Patients with pre-existing viral hepatitis (n = 9) were not
excluded because the clinical basis of their hospital
admission was due to AH. Demographical and laboratory
data were extracted by reviewing the electronic medical
charts. Survival at 30- and 90-days following hospital
admission was established by chart review or phone con-
tact, if necessary. Therapy for AH was also assessed.
According to local protocol, patients with a severe AH
(DF ≥32) were given a single daily dose of oral predniso-
lone 40 mg for 28 days, in addition to supportive ther-
apy including gastric acid suppressors, high dose vitamin
B and C, vitamin K, dietary supplements often by enteral
feeding, and chlordiazepoxide if there were alcohol
withdrawal symptoms. In those unable to take oral
medication, 32 mg/day of methylprednisolone were
722 Aliment Pharmacol Ther 2014; 39: 721-732
ª 2014 The Authors. Alimentary Pharmacology & Therapeutics published by John Wiley & Sons Ltd.
V. Papastergiou et al.
administered intravenously. Patients placed on steroids,
presence of contraindications to steroid treatment and
the exact date of initiation of steroid therapy were all
recorded by retrospectively reviewing medical charts.
Derivation of prognostic models
For each patient, laboratory values obtained on the day
of hospital admission were used to calculate prognostic
models according to their formulas (Table 1). MELD,27
MELD-Na,28 UKELD,29 GAHS,13 ABIC14 and DF12 were
all re-calculated using laboratory data from day 7 after
admission to establish whether 1-week rescoring could
be associated with an improved predictive performance,
as outlined previously.13, 17, 30, 31 The Lille score is a
combination of six reproducible variables incorporating a
dynamic one (i.e. the 1-week evolution in bilirubin).19
Table 1 | Formulas and included variables in prognostic models for alcoholic hepatitis
Bilirubin Creatinine
PT/
INR Age Albumin Urea Leucocytes Na D Bilirubin
MELD27
9.57 9 loge (creatinine, mg/dL) + 3.78
9 loge (bilirubin mg/dL) + 11.20
9 loge (INR) + 6.43
+ + +      
DF12
4.6 9 (patient’s PT  control PT)
+ bilirubin (mg/dL)
+ + +      
*GAHS13
Age (<50 years = 1, ≥50 years = 2)
+ Leucocytes (109/L) (<15 = 1, ≥15 = 2)
+ Urea (mmol/L) (<5 = 1, ≥5 = 2)
+ PT ratio (<1.5 = 1, 1.5–2.0 = 2,
>2.0 = 3) + bilirubin (mmol/L) (<125 = 1,
125–50 = 2,
<250 = 3)
+  + +  + +  
ABIC14
(Age in years 9 0.1) + (bilirubin
mg/dL 9 0.08) + (creatinine mg/dL
9 0.3) + (INR 9 0.8)
+ + + +     
MELD-Na28
MELD – Na  [0.025 9 MELD 9
(140  Na)] + 140 (where the serum
sodium concentration is bound
between 125 and 140 mmol per litre)
+ + +     + 
UKELD29
5 9 [1.5 9 loge (INR) + 0.3 9
loge (creatinine mmol/L) + 0.6 9
loge (bilirubin mmol/L)  13 9
loge (Na) + 70]
+ + +     + 
Lille19
R-Lille model = 3.19  0.101
9 (age in years) + 0.147 9 (albumin
day 0 in g/L) + 0.0165 9 (bilirubin-day 0
–bilirubin-day 7 (mmol/L))  0.206 9
(renal insufﬁciency^)  0.0065 9
(bilirubin-day 0 mmol/l)  0.0096 9
(PT in seconds); Lille model = exp (R)/
(1 + exp (R))
+ + + + +    +
PT, prothrombin time; INR, international normalised ratio; MELD, model for end-stage liver disease; DF, Maddrey’s discriminant
function; GAHS, Glascow alcoholic hepatitis score; ABIC, age, bilirubin, international normalised ratio and creatinine score; MELD-
Na, modiﬁed MELD including sodium; UKELD, United Kingdom model for end-stage liver disease.
* Rather than a formula, GAHS is based on a scoring system.
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This model, as well as ECBL21 and a 25% fall in bilirubin
levels,22 do not have the same prognostic basis and so
cannot be compared to other models, as they were spe-
ciﬁcally developed for the assessment of corticosteroid
response. Thus, these three scores were validated sepa-
rately in a subgroup of patients with severe AH (admis-
sion DF ≥32) treated with corticosteroids, using clinical
and biochemical parameters obtained on the day before
treatment start and the evolution in bilirubin at day 7 of
treatment with steroids.
Statistical analyses
Baseline characteristics of the study population were
compared by using Chi-squared test for categorical data
and Student t-test or Mann–Whitney U test for continu-
ous data, as appropriate. Occurrence of death due to any
cause within 30 or 90 days from the hospital admission
was the study endpoint. Mortality rates were calculated
as the proportion of patients that died within these time
intervals. In patients with severe AH (admission DF
≥32), a Cox proportional hazards model was evaluated
to assess the crude and adjusted effect of corticosteroid
therapy with respect to either 30- and 90-day mortality.
The utility of each model to predict 30- or 90-day mor-
tality was evaluated using receiver operating characteris-
tics (ROC) curves, and the area under the receiver
operating characteristics curves (AUROCs) was calcu-
lated. In this analysis, a model with an AUROC between
0.7 and 0.8 was considered clinically useful and between
0.8 and 0.9 as having very good diagnostic accuracy. If
the AUROC approaches 1.0, the model approaches 100%
sensitivity and speciﬁcity, indicating a perfect diagnostic
test.32 Sensitivity, speciﬁcity, positive predictive value
(PPV) and negative predictive value (NPV) of the mod-
els were calculated using originally published cut-offs: 32
for DF, 9 for GAHS, 21 for MELD, 28 for MELD-Na,
6.71 and 9 for the ABIC and 0.45 for the Lille
score.12, 14, 16, 18–20 As no disease-speciﬁc calibration has
been reported for UKELD, we calculated optimised pre-
dictive performances using the best cut-off within our
cohort (point nearest to the top left corner of the ROC
curve, yielding the best relationship between sensitivity
and speciﬁcity). Comparison between AUROCs was per-
formed by the method of Hanley and McNeil32 and the
P-values obtained were considered indicative of nonsimi-
larity if below 0.05. All analyses were performed using
the SPSS version 22 (SPSS, IBM, Chicago, IL, USA) except
for the comparisons between AUROCs which were per-
formed using MedCalc version 12.2.0 (Medisoftware,
Mariakerke, Belgium).
RESULTS
Study cohort, biochemical data and scores of the
different predictive models
Seventy-one consecutive patients with a biopsy-proven
diagnosis of AH who met the inclusion criteria, com-
prised the study population. The baseline clinical data
and prognostic score values are shown in Table 2. There
were 47 males and 24 females with a median age of
49 years. Median admission MELD and DF were 18.8
and 47.5 respectively. The median interval between
admission and the date of liver biopsy was 1.5 days
(range: 0–6 days). This time interval was comparable
between survivors and patients who died either within
30 days (P = 0.28) and 90 days (P = 0.76) from hospital
admission. Overall, the 30-day mortality was 14.1% (10/
71), whereas the 90-day mortality was 19.7% (14/71).
The differences between survivors and nonsurvivors at
30 and 90 days from admission are shown in Table 2.
With respect to 30-day mortality, patients who died had
a higher admission median bilirubin, urea, creatinine,
prothrombin time and INR, higher prognostic score val-
ues, lower albumin and were more frequently females as
compared to patients who survived (Table 2a). Similar
differences were detected with respect to 90-day mortal-
ity (except there were no signiﬁcant gender differences
and there was a trend for higher admission leucocyte
count in those who died), and when comparisons were
repeated by taking into account the 1-week biochemical
values and scores (Table 2b). Considering the subgroup
of patients with severe AH (admission DF ≥32; n = 49),
patients who died at 30 days (n = 10) had a lower med-
ian albumin (26 vs. 30 g/L; P = 0.04) and were margin-
ally more frequently of female gender (6/10 vs. 11/39;
P = 0.07). With respect to 90-day mortality, patients
with a severe AH who died (n = 14) had a lower admis-
sion median albumin (27 vs. 30 g/L; P = 0.05) and a
higher median creatinine (74.5 vs. 53 mmol/L; P = 0.05)
as compared to those who survived, whereas no other
differences were detected between the two groups con-
sidering all 30-/90-day variables included in Table 2
(data not shown).
Data on corticosteroid treatment
Overall, 49 (69%) patients had a DF ≥32 at presentation
and 34 (69.4%) were treated with corticosteroids,
whereas no patient received pentoxyﬁlline or other
speciﬁc treatment for AH. Contraindications for cortico-
steroid treatment included variceal bleeding in 3 patients
and infection in 5 patients, including 2 patients with
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spontaneous bacterial peritonitis (diagnosed by a neutro-
phil count ≥250 cc/mm3 in the ascitic ﬂuid), whereas
another two patients refused corticosteroid treatment. In
ﬁve patients, the decision for not treating with corticos-
teroids was based on the clinical judgment of the treat-
ing physician, despite no obvious treatment
contraindications. Mean time between admission to
Royal Free Hospital and start of corticosteroid treatment
was 2.44  1.88 days (range: 0–8 days). That time
interval was comparable between patients who survived
at 30 (2.64  1.98) and 90 days (2.61  1.88) and
those who did not (1.5  0.84; P = 0.19 and
1.87  1.88; P = 0.21, respectively). Considering 49
patients with an admission DF ≥32 (i.e. those expected
to beneﬁt from corticosteroids22), the 30-day survival
rate was 28/34 (82.4%) in steroid-treated patients vs. 11/
15 (73.3%) in nontreated (P = 0.47). At 90 days, the
survival rate was 26/34 (76.5%) in patients receiving
corticosteroids vs. 9/15 (60%) in nontreated (P = 0.31).
In patients with a severe AH (admission DF ≥32), the
crude hazard ratio (HR) for corticosteroid treatment
was 0.57 [95% conﬁdence interval (CI): 0.16–2.05;
P = 0.40) with respect to 30-day mortality and 0.55
(95% CI: 0.19–1.58; P = 0.27) with respect to 90-day
mortality. Lack of a signiﬁcant corticosteroid effect on
mortality persisted after adjustment for admission
Table 2 | Comparison of admission and 1 week variables and scores between patients who survived at 30- and 90-
days and those who died. All quantitative variables are given as medians (range)
Variable
Total cohort
(n = 71)
30-day
survivors
(n = 61)
30-day
nonsurvivors
(n = 10) P-value
90-day
survivors
(n = 57)
90-day
nonsurvivors
(n = 14) P-value
a, Admission
Age (years) 49 (26–75) 49 (26–75) 50 (30–57) 0.69 49 (26–72) 50 (30–75) 0.79
Male Gender n (%) 47 (66.2) 43 (70.5) 4 (40) 0.08 39 (68.4) 8 (57.1) 0.53
Bilirubin (lmol/L) 212 (44–827) 187 (44–827) 241 (144–711) 0.09 178 (44–827) 356 (144–711) 0.006
Albumin (g/L) 30 (19–42) 32 (19–42) 26 (20–34) 0.006 32 (19–42) 27 (20–34) 0.005
Creatinine (lmol/L) 57 (31–292) 54 (31–240) 74.5 (31–292) 0.02 53 (31–240) 74.5 (31–292) 0.03
Urea (mmol/L) 3.5 (0.8–17.3) 3.4 (0.8–17.3) 6.7 (2.8–15) 0.04 3.4 (0.8–12.8) 5.4 (2.3–17.3) 0.08
Sodium (mmol/L) 133 (121–155) 136 (131–155) 133 (121–144) 0.09 134 (121–155) 133 (121–144) 0.72
Prothrombin time (s) 22.2 (12.2–45.4) 21.8 (12.2–45.4) 26.1 (16.1–39.6) 0.03 21.7 (12.2–45.4) 24.5 (16.1–39.6) 0.02
INR 1.8 (0.9–4) 1.7 (0.9–4) 2.2 (1.3–3.2) 0.02 1.7 (0.9–4) 2.2 (1.3–3.2) 0.009
Leucocytes (109/L) 11.2 (2.8–34.7) 11.2 (2.8–25.2) 11.8 (9.2–34.7) 0.21 11.2 (2.8–25.2) 11.8 (9.2–34.7) 0.08
DF 47.5 (2.2–157.7) 42.3 (2.2 157.7) 57.4 (34–150.1) 0.04 40.1 (2.2–157.7) 58.3 (34–150.1) 0.007
GAHS 8 (5–12) 8 (5–12) 10 (7–12) 0.009 8 (5–12) 10 (7–12) 0.001
ABIC score 7.8 (4.4–12.1) 7.6 (4.4–11.6) 9.4 (6.9–12.1) 0.03 7.5 (4.4–11.6) 9.5 (6.9–12.1) 0.001
MELD score 18.8 (7.9–40.3) 18.7 (7.9–36.9) 25.6 (15.4–40.3) 0.004 18.2 (7.9–36.9) 25.4 (15.4–40.3) 0.0001
MELD-Na score 21.2 (6.3–40.2) 20.3 (6.3–38.2) 23.6 (15.4–40.2) 0.08 20.2 (6.3–38.2) 26.4 (15.4–40.2) 0.003
UKELD score 57.7 (48.7–72.8) 57.7 (48.7–72.8) 57.5 (52.7–69.2) 0.52 56.8 (48.7–72.8) 59.6 (52.7–69.2) 0.04
(n = 63) (n = 56) (n = 7) (n = 52) (n = 11)
b, Day 7 from admission
Bilirubin (lmol/L) 146 (25–647) 128 (25–647) 214 (165–568) 0.01 120.5 (25–647) 420 (165–568) 0.0001
Creatinine (lmol/L) 55 (26–343) 54 (26–101) 154 (36–343) 0.02 54 (26–101) 95 (36–343) 0.007
Urea (mmol/L) 4.1 (1.6–22.3) 4.1 (1.6–20.8) 9 (2.8–22.3) 0.04 4.1 (1.6–20.8) 8.9 (2.8–22.3) 0.07
Sodium (mmol/L) 136 (111–161) 137 (125–161) 136 (111–149) 0.51 136.5 (111–149) 133 (125–161) 0.25
Prothrombin time (s) 20 (1.5–55.5) 19.8 (16–35.1) 23.9 (17.1–55.5) 0.009 19.8 (16–35.1) 23.2 (17.1–55.5) 0.02
INR 1.6 (0.9–16) 1.6 (0.9–3.1) 2.1 (1.4–4.8) 0.004 1.6 (0.9–3.1) 1.9 (1.4–4.8) 0.01
Leucocytes (109/L) 11 (3.6–34.1) 10.9 (3.6–34.1) 11.8 (5–31.1) 0.66 10.9 (3.6–34.1) 11.9 (5–31.1) 0.46
DF 28.2 (1.46–194.2) 27.6 (1.5–125.7) 50.9 (34.4–194.2) 0.002 27.2 (1.5125.7) 48.6 (34.4–194.2) 0.001
GAHS 8 (5–12) 7 (5–12) 9.5 (8–11) 0.01 7 (5–12) 9 (8–11) 0.003
ABIC score 7.2 (4.1–17.4) 7.1 (4.1–17.4) 8.3 (6.9–11) 0.04 7 (4.1–17.4) 7.9 (6.9–11) 0.02
MELD score 15.7 (1.38–46.5) 15.1 (1.4–34.1) 28.7 (13.9–46.5) 0.002 14.6 (1.4–34.1) 25.6 (13.9–46.5) 0.0001
MELD-Na score 18.5 (7.3–44.1) 18.4 (7.3–34.4) 27.8 (14.8–44.1) 0.01 17.9 (7.3–34.4) 25.6 (14.8–44.1) 0.001
UKELD score 55.5 (43.2–72.8) 55.4 (43.2–68.3) 60.6 (48.4–72.8) 0.08 55 (43.2–68.3) 61.7 (48.4–72.8) 0.006
INR, international normalised ratio; DF, Maddrey discriminant function; GAHS, Glascow alcoholic hepatitis score; ABIC, age,
bilirubin, INR, creatinine score; MELD, model for end-stage liver disease; MELD-Na, modiﬁed MELD including sodium; UKELD,
United Kingdom model for end-stage liver disease.
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variables differing (P < 0.1) between survivors and non-
survivors (i.e. gender and bilirubin with respect to
30-day mortality; creatinine and albumin for 90-day
mortality), yielding for 30-day mortality: HR = 0.69
(95% CI: 0.19–2.50; P = 0.57) and for 90-day mortality:
HR = 0.56 (95% CI: 0.18–1.71; P = 0.31).
Use of the MELD, DF, GAHS, ABIC, MELD-Na and
UKELD for the assessment of 30- and 90-day
mortality
The ROC curves of the models with respect to 30-day
and 90-day mortality are shown in Figure 1. The AU-
ROCs for the prediction of 30-day mortality ranged from
0.56 for UKELD to 0.79 for MELD and for the predic-
tion of 90-day mortality between 0.68 (UKELD) and
0.84 for MELD (Table 3A). No signiﬁcant differences
were found in pairwise comparisons between the
AUROCs of the different models (data not shown).
Re-calculation of the scores at day 7 from admission was
possible for 63 patients; three patients died before day
seven, and ﬁve patients (all of whom survived) did not
have all the required biochemical data available at this
time point. Re-scoring on day 7 generally yielded a trend
towards increased AUROCs, ranging to 0.69–0.85 for
30-day and 0.75–0.86 for 90-day mortality (Table 3B).
However, none of the differences reached statistical sig-
niﬁcance, and there were no statistically signiﬁcant dif-
ferences in the pairwise comparisons between models
(data not shown). Figure S1 shows scatter plots of
admission score values related to 30- and 90-day mortal-
ity, including representation of both originally published
and optimal cut-off points within our cohort. The later
were 44 for DF, 28 for MELD-Na and 56 for UKELD. A
high ABIC cut-off of 9.5 resulted in increased speciﬁcity
as compared to the originally suggested value of 9 (90%
vs. 80% and 95% vs. 84% for a 30- and 90-day outcome
respectively). Previously suggested MELD (21), GAHS
(9) and low ABIC (6.7) cut-off points performed opti-
mally within our cohort.13, 14, 16 Using originally pro-
posed cut-points, the negative predictive values (NPV)
for ruling out short-term mortality were high (mostly
exceeding 90%), whereas ability of the models to cor-
rectly predict occurrence of death (positive predictive
value; PPV) was substantially lower, in most cases less
than 50% (range: 17–57%) (Table 3a). These properties
remained largely unchanged when the predictive perfor-
mances of the models were re-assessed 1 week from
admission (NPV: 0.85–1.00, PPV: 0.20–0.57; Table 3b).
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Figure 1 | Receiver operating characteristic curve of the different prognostic scores for alcoholic hepatitis calculated
on admission, used to predict 30-day (a) and 90-day (b) mortality.
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Models proposed to assess corticosteroid
responsiveness
Calculation of the ECBL, a fall in serum bilirubin by
25% and the Lille score was possible for 31 of 34
patients with severe AH (admission DF ≥32) receiving
corticosteroids; two patients died before day 7 of corti-
costeroids, whereas an additional patient did not have all
the required biochemical data. Comparisons in biochem-
ical and clinical parameters between corticoste-
roid-treated patients who survived and those who died
(six patients by day 30 and eight patients by day 90) are
shown in Table 4. After 1 week of corticosteroids, 14
(45.2%) patients had a 25% fall in bilirubin from base-
line, 22 (71%) had an ECBL, and 22 (71%) achieved a
Lille response using the proposed cut-point of 0.45. The
AUROC analysis and operational characteristics of the
three models with respect to 30- and 90-day mortality
are shown in Figure 2. Overall, no statistically signiﬁcant
differences were found in AUROC comparisons between
the different models relative to either a 30- and 90-day
outcome. Notably, a good response to corticosteroids
according to all three criteria yielded an excellent NPV
for excluding short-term mortality (>85%), whereas the
PPVs were substantially lower, in all cases <60%.
DISCUSSION
The present study is an external evaluation of nine prog-
nostic models of AH using a 100% biopsy-proven
Table 3 | The AUROC and optimal operational characteristics in predicting 30- and 90-day mortality for the different
prognostic scores calculated on the day of admission (a) and re-calculated after 7 days (b)
Score AUROC Std. err 95% CI Sensitivity* Speciﬁcity* PPV* NPV*
a, Admission (n = 71)
30-day mortality
MELD 0.79 0.085 0.62–0.95 0.80 0.79 0.38 0.96
DF 0.71 0.092 0.53–0.89 1.00 0.36 0.20 1.00
GAHS 0.75 0.073 0.61–0.89 0.90 0.59 0.27 0.94
ABIC 0.71 0.079 0.55–0.86 1.00/0.60 0.20/0.80 0.17/0.33 1.00/0.92
MELD-Na 0.68 0.087 0.50–0.84 0.30 0.82 0.22 0.88
UKELD 0.56 0.087 0.39–0.73 0.90 0.43 0.21 0.96
90-day mortality
MELD 0.84 0.064 0.71–0.96 0.86 0.84 0.57 0.96
DF 0.74 0.062 0.61–0.86 1.00 0.39 0.29 1.00
GAHS 0.78 0.060 0.67–0.90 0.93 0.63 0.38 0.97
ABIC 0.78 0.072 0.64–0.92 1.00/0.64 0.21/0.84 0.24/0.50 1.00/0.91
MELD-Na 0.76 0.069 0.62–0.89 0.43 0.86 0.43 0.86
UKELD 0.68 0.076 0.53–0.83 0.93 0.46 0.30 0.96
b, Day 7 from admission (n = 63)
30-day mortality
MELD 0.84 0.084 0.68–1.00 0.60 0.87 0.43 0.93
DF 0.85 0.058 0.74–0.96 1.00 0.48 0.24 1.00
GAHS 0.77 0.070 0.63–0.91 0.60 0.70 0.25 0.91
ABIC 0.74 0.092 0.54–0.90 0.80/0.30 0.46/0.93 0.20/0.43 0.94/0.89
MELD-Na 0.78 0.090 0.61–0.96 0.40 0.93 0.40 0.92
UKELD 0.69 0.106 0.48–0.89 0.50 0.69 0.21 0.89
90-day mortality
MELD 0.86 0.062 0.73–0.98 0.50 0.88 0.50 0.88
DF 0.84 0.054 0.73–0.94 1.00 0.51 0.33 1.00
GAHS 0.79 0.061 0.67–0.91 0.64 0.74 0.37 0.89
ABIC 0.75 0.077 0.58–0.88 0.79/0.29 0.49/0.95 0.28/0.57 0.90/0.57
MELD-Na 0.83 0.068 0.69–0.96 0.36 0.91 0.50 0.85
UKELD 0.77 0.084 0.60–0.93 0.57 0.72 0.33 0.87
AUROC, area under the receiver operating characteristics curve; Std. err, standard error; CI, conﬁdence interval; PPV, positive pre-
dictive value; NPV, negative predictive value; MELD, model for end-stage liver disease; DF, Maddrey discriminant function; GAHS,
Glascow alcoholic hepatitis score; ABIC, age, bilirubin, international normalised ratio and creatinine score; MELD-Na, modiﬁed
MELD including sodium; UKELD, United Kingdom model for end-stage liver disease.
* Cut-off values used: MELD: 21, DF: 32, GAHS: 9, ABIC: 6.71/9, MELD-Na: 28, UKELD: 56.
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Table 4 | Clinical and biochemical parameters used for the calculation of the Lille score in patients with severe
alcoholic hepatitis (admission Maddrey ≥32) treated with corticosteroids (n = 31). Comparisons regard patients who
survived at 30- and 90-days and those who died. Quantitative variables are given as medians (range)
Variable
30-day survivors
(n = 25)
30-day nonsurvivors
(n = 6) P-value
90-day survivors
(n = 23)
90-day nonsurvivors
(n = 8) P-value
Age (years) 49 (26–59) 50 (30–54) 0.88 49 (26–59) 49 (26–59) 0.96
Male gender n (%) 21 (84) 3 (50) 0.11 19 (82.6) 5 (62.5) 0.33
Bilirubin-day 0 (lmol/L) 328 (87–786) 397 (176–647) 0.63 318 (87–768) 456.5 (176–647) 0.31
Bilirubin-day 7 (lmol/L) 209 (45–768) 368 (175–851) 0.09 202 (45–768) 427.5 (175–851) 0.03
DBilirubin (lmol/L) 64 (117–286) 31.5 (204–87) 0.03 64 (117–286) 31.5 (204–129) 0.03
Albumin (g/L) 30 (18–41) 28.5 (20–36) 0.25 30 (18–41) 28.5 (20–36) 0.25
Creatinine (lmol/L) 53 (29–209) 103.5 (26–267) 0.05 52 (29–209) 90 (26–267) 0.03
Prothrombin time (s) 23 (18.7–35.6) 26 (18.3–50.5) 0.09 23.8 (18.7–35.6) 23.5 (18.3–50.5) 0.23
INR 2 (1.4–3.1) 2.25 (1.4–4.7) 0.12 2 (1.4–3.1) 2.15 (1.4–4.7) 0.16
Lille score 0.14 (0.01–0.91) 0.75 (0.18–0.99) 0.02 0.09 (0.01–0.91) 0.75 (0.14–0.99) 0.009
1.0
30-day mortality
25% fall in bilirbin
ECBL
LIIIe model
25% fall in bilirbin
ECBL
LIIIe model
90-day mortality
1.0
0.8
0.8
0.6
0.6
0.4
0.4
1- Specificity
Diagonal segments are produced by ties.
Score AUROC Std. err 95% CI Sensitivity Specificity PPV
0.44
0.35
0.44
0.56
0.56 0.86
0.93
0.86
0.91
0.91
1.00
NPV
0.41
0.80
0.56
0.80
0.830.63
0.57
0.83
30-day mortality
90-day mortality
0.67
0.88
0.63
1.00
0.67
0.49-0.98
0.62-0.94
0.66-0.97
0.50-0.95
0.53-0.91
0.66-0.97
0.123
0.084
0.019
0.113
0.099
0.0790.82
*Using a Lille score cut-point of 0.4519.
0.73
0.78
0.81
0.73
0.72
AUROC, area under the receiver operating curve; ECBL, early change in bilirubin levels; CI, confidence interval; 
PPV, positive predictive value; NPV, negative predictive value.
ECBL
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25% fall in
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baseline
Lille score*
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Figure 2 | AUROC analysis and operational characteristics for three different indicators of response to corticosteroid
treatment, used to predict 30-day (a) and 90-day (b) mortality.
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cohort, including the ﬁrst disease-speciﬁc assessment of
the UKELD used for prioritizing liver recipients in UK.33
Overall, MELD, DF, GAHS and the ABIC proved to be
clinically useful scores, performing comparably and with
an acceptable accuracy (AUROCs exceeding 0.70) for
both 30- and 90-day mortality. Our ﬁndings are congru-
ent with those of previous validation studies in which,
however, diagnosis of AH was based solely on clinical
grounds. In a Danish study including 274 patients,
MELD, MELD-Na, GAHS, Lille score and the ABIC also
performed comparably in predicting 28-, 84- and
180-day mortality.30 Similarly, in another study, MELD,
DF, ABIC and GAHS performed equally in predicting
short-term (30- and 90-day) survival, although all mod-
els were uniformly poor in predicting longer-term
(6-month and 1-year) outcome.34 In a prospective com-
parison of 182 patients, DF, GAHS, MELD and ABIC
performed well with no statistically signiﬁcant difference
for either 28 or 90 days mortality after admission.35 We
observed a tendency towards better prognostic accuracies
with respect to 90-day mortality (90-days AUROCs:
0.68–0.86 vs. 30-days AUROCs: 0.56–0.79), and when
assessment of prognosis was repeated 1 week from
admission (90-days AUROCs: 0.75–0.86 and 30 day AU-
ROCs: 0.69–0.85). This is consistent with previous obser-
vations on the utility of repeated scoring, 6–9 days from
hospital admission.13, 17, 30, 31
DF was developed several decades ago based on
patient cohorts that might have had different supportive
care than in current patients. Our study, in agreement
with previous observations, indicates an inadequate spec-
iﬁcity (<40%) for mortality of DF: 39/49 (79.6%) of
patients with DF ≥32 were alive by day 30 and 35/49
(71.4%) by day 90. Obsolescence of the cut-point of 32
may account, at least partially, for the inaccuracy of DF,
and higher cut-offs have been proposed: 37 in the study
by Dunn et al.,16 and 42 in the study by Sheth et al.15
Optimal cut-off within our cohort corresponds to 44,
although even by using this value, speciﬁcity of DF
would be still less than 60%. This inaccuracy of DF has
been suggested as the basis of the long-standing debate
on the efﬁcacy of corticosteroid treatment.13 Moreover,
poor standardisation of PT across different laboratories
represents another limitation affecting the reproducibility
of this index.36
Previous studies15–17 have proposed use of MELD as
an alternative model, more speciﬁc for mortality, as
compared to DF. As well as INR which has problems in
reproducibility of measurement,36 MELD includes creati-
nine, a relevant prognostic indicator in AH, but which
measurement in a context of hyper-bilirubinemia is also
problematic.37 Our data, consistent with these older
reports, shows sensitivity/speciﬁcity of 0.80/0.79
(30-days) and 0.86/0.84 (90-days) for the MELD vs.
1.00/0.36 (30-days) and 1.00/0.39 (90-days) for the DF.
In a study by Srikureja et al., 1-week MELD has been
shown to be more accurate, as compared to admission
MELD, for the prediction of in-hospital mortality.17 Our
results are further validating this observation with
respect to both the prediction of 30-day (AUROC: 0.84
for 1 week MELD vs. 0.79 for admission MELD) and
90-day risk of death (AUROC: 0.86 for 1 week MELD
vs. 0.84 for admission MELD). However, in contrast to
this last study, we could not identify any advantage in
1-week re-testing of MELD over DF, as re-calculation of
the DF 1 week from admission also yielded excellent
prognostic accuracies (AUROC >0.80), comparable to
those obtained by recalculating MELD. Disease-speciﬁc
calibration of MELD is an issue: in our cohort the opti-
mal cut-off value was 21, similarl to the study by Dunn
et al.16 However, lower thresholds such as 11 reported
by Sheth et al.15 and 18 reported by Shrikureja et al.17
have been proposed, probably reﬂecting differences in
the grade of severity of disease between different cohorts.
Neither MELD-Na nor UKELD, both modiﬁcations of
MELD incorporating sodium, were prognostically supe-
rior to classical MELD within our cohort. Previously,
MELD-Na was shown a stronger predictor of 180-day
mortality (vs. MELD) when patients with clinically diag-
nosed AH and ascites were considered. However, the
small sample size in this study (26 patients, 13 with asci-
tes) precludes deﬁnitive conclusions.18
GAHS and ABIC are disease-speciﬁc formulas which
also include creatinine14, 20 but are easier to calculate at
the bedside in comparison to MELD. The ABIC score
includes similar parameters as the MELD score, except
for patient’s age, whereas GAHS is the only index to
consider an inﬂammatory parameter (white cell count)
(Table 1). Although GAHS and ABIC have been shown
to perform signiﬁcantly better than DF within their
internal validation cohorts, our results suggest compara-
ble predictive accuracies of these three models. In a head
to head comparison of GAHS and ABIC using 181
patients from the GAHS validation cohort, the two mod-
els also performed equally.31 ABIC is a dual cut-off
model which generates a trichotomous classiﬁcation into
low, intermediate and high risk of death.14 Critically,
such ability was questioned in a recent study in which
the 3 stages did not result in differences in 90-day out-
comes between the ‘low’ and ‘intermediate’ groups,
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although there was a clearly worse outcome in those
with ABIC >9.35 Unfortunately, the relatively small num-
ber of events precluded us from undertaking a similar
analysis.
The Lille score is a combination of six reproducible
variables including a dynamic one, i.e. the evolution in
bilirubin following 1 week of corticosteroid treatment.19
Within our biopsy-proven cohort, use of the Lille model
proved an accurate predictor of both 30- and 90-day
outcome (AUROC 0.81/0.82). However, our data do not
justify its complexity over the much easier bedside calcu-
lation of ECBL and 25% fall in bilirubin, both perform-
ing with an acceptable grade of accuracy within our
cohort (AUROC 0.72–0.78). Our ﬁndings are congruent
with those of a recent prospective assessment, in which,
however, diagnosis of AH relied solely on clinical crite-
ria.35 As availability of 7-day biochemical data are neces-
sary in order to calculate the Lille score, it is interesting
to note that re-calculation at 7 days of either the MELD
or DF, also provided excellent predictive accuracies (AU-
ROCs >0.80).However, their dynamic evolution (i.e.
DΜELD and DDF) has been reported to have less prog-
nostic power in comparison with changes in Lille score.19
Thus, the Lille model represents the best currently vali-
dated dynamic criterion for the assessment of mortality
in AH, and the only one linked to speciﬁc stopping rules
for corticosteroid management: in poor responders (Lille
>0.45) discontinuation of corticosteroids is recom-
mended,19 particularly when Lille >0.56 (i.e. considered
null responders).4, 10
Importantly, all prognostic models and in particular
DF, MELD, GAHS, ABIC and the Lille score showed
excellent NPV, in most cases exceeding 90%. This is in
contrast with PPV which were low, in most instances
lower than 50% (Table 3). This ﬁnding suggests that the
paradigm in clinical decision making and the designation
of clinical trials targeting speciﬁc treatments in AH,
should be to exclude low-risk patients, rather than to
identify those with high death risk, using these models.
Clearly, some patients identiﬁed at high risk may
receive futile treatment but evaluating different thresh-
olds or different weighting or new variables may reﬁne
prognosis.
The present study has limitations. We did not per-
form a sample size calculation, and our study cohort was
based on the available patients but it does reﬂect a
4-year single-centre experience of histologically diag-
nosed AH. Therefore, although our sample size is com-
parable16 and more than double15 than that of previous
publications, our study may be underpowered to detect a
signiﬁcant difference in the predictive performances
between models. This is more likely to be true in the
analysis of the Lille score and its variants, which was
restricted to 31 patients receiving corticosteroids. Treat-
ment with corticosteroids may have led in underestima-
tion of the predictive ability of general prognostic scores,
although a survival beneﬁt conferred by this treatment
remains in some dispute8, 9 and corticosteroid-treated
patients have been previously included for the develop-
ment and/or validation of the models.14, 16 Despite
adjustment for confounding variables there was no
demonstrable corticosteroid effect on survival, which is
unsurprising, considering that our study was not
designed nor powered to detect a therapeutic effect.
However, this may indicate that treatment effects are not
a signiﬁcant source for biassing predictive performances
in the present study. Transjugular liver biopsy23 is rou-
tinely performed in our institution whenever AH is sus-
pected. Although inclusion of less severe cases by this
institutional policy (and thus changes in predictive accu-
racies of the models) could be possible, the admission
MELD in our series is comparable to that of other
cohorts in which diagnosis of AH relied solely on clinical
criteria.16, 30 Congruently, the 30- and 90-day mortality
in our cohort was 14.1% and 17.9% respectively, which
is consistent with previous studies reporting short-term
mortality ranging to 14.4–27%.15–17, 30
In conclusion, the negative predictive values of MELD,
DF, GAHS and the ABIC as well as those of three differ-
ent scores to assess corticosteroid response, proved to be
valid for prognostication when assessed in an indepen-
dent cohort of patients with biopsy-proven AH. In our
series, both MELD-Na and UKELD did not confer any
prognostic advantage in comparison with classical
MELD. The choice of prognostic model thus depends on
other factors including ease of use, routine use of corti-
costeroids according to institutional practice and the per-
sonal preferences of the treating physician. However,
there is still room for further reﬁnement, and efforts for
improved prognostic models should continue, as there is
increasing need for accurate prognostic stratiﬁcation in
AH, particularly with the possibility of early liver trans-
plantation.35, 38 Thus, it is important currently to rely on
response criteria to corticosteroids, or non-improvement
at 7-days if liver transplantation is considered, as the
PPV of all models is insufﬁcient to establish a poor
prognosis at admission.
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